FDA Advisory Panel Gives Unanimous Thumbs Up to BMS' Orencia

Drug Industry Daily
KEYWORDS FDA
A A

The FDA’s Arthritis Advisory Committee voted unanimously Sept. 6 to recommend approval for Bristol-Myers Squibb’s (BMS) rheumatoid arthritis (RA) drug candidate Orencia.

To View This Article:

Login

Subscribe To Drug Industry Daily